{"id":500,"date":"2016-05-25T08:10:38","date_gmt":"2016-05-25T13:10:38","guid":{"rendered":"https:\/\/3sixtypharma.com\/?p=500"},"modified":"2016-05-25T08:12:10","modified_gmt":"2016-05-25T13:12:10","slug":"cutting-edge-oncology-research-progresses-quickly-anticipated","status":"publish","type":"post","link":"https:\/\/3sixtypharma.com\/2016\/05\/25\/cutting-edge-oncology-research-progresses-quickly-anticipated\/","title":{"rendered":"Cutting edge oncology research progresses more quickly than anticipated"},"content":{"rendered":"<p><a href=\"http:\/\/bit.ly\/1YYH5lY\" target=\"_blank\"><span style=\"font-size: 16pt; font-family: 'arial black', sans-serif;\">Redx Pharma reaches pre-clinical proof of concept stage with oncology lead<\/span><\/a><\/p>\n<p><span style=\"font-size: 12pt; font-family: arial, helvetica, sans-serif;\">Chronic Lymphocytic Leukaemia (CLL) patients commonly develop resistance to gold-standard?therapy (the?irreversible Bruton&#8217;s Tyrosine Kinase [BTK] inhibitor,?ibrutinib)?due to a?genetic mutation. ?<\/span><\/p>\n<p><span style=\"font-size: 12pt; font-family: arial, helvetica, sans-serif;\">Redx&#8217;s new candidate is?a reversible BTK inhibitor and could target?resistant CLL?and other blood cancers.<\/span><\/p>\n<p><span style=\"font-size: 12pt; font-family: arial, helvetica, sans-serif;\">Could be a significant step in the potential advancement of CLL treatment.<\/span><\/p>\n<blockquote class=\"twitter-tweet\" data-width=\"550\" data-dnt=\"true\">\n<p lang=\"en\" dir=\"ltr\">Cutting edge oncology research-Redx&#39;s experimental BTK inhibitor for resistant  CLL shows progress. <a href=\"https:\/\/twitter.com\/hashtag\/3SixtyPharmaSME?src=hash&amp;ref_src=twsrc%5Etfw\">#3SixtyPharmaSME<\/a> <a href=\"https:\/\/t.co\/3YcmncRkYz\">https:\/\/t.co\/3YcmncRkYz<\/a><\/p>\n<p>&mdash; 3SixtyPharma (@3SixtyPharma) <a href=\"https:\/\/twitter.com\/3SixtyPharma\/status\/735449831376838656?ref_src=twsrc%5Etfw\">May 25, 2016<\/a><\/p><\/blockquote>\n<p><script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Redx Pharma reaches pre-clinical proof of concept stage with oncology lead Chronic Lymphocytic Leukaemia (CLL) patients commonly develop resistance to gold-standard?therapy (the?irreversible Bruton&#8217;s Tyrosine Kinase [BTK] inhibitor,?ibrutinib)?due to a?genetic mutation. ? Redx&#8217;s new candidate is?a reversible BTK inhibitor and could target?resistant CLL?and other blood cancers. Could be a significant step in the potential advancement of<a href=\"https:\/\/3sixtypharma.com\/2016\/05\/25\/cutting-edge-oncology-research-progresses-quickly-anticipated\/\">[&#8230;]<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","enabled":false}}},"categories":[8],"tags":[],"class_list":["post-500","post","type-post","status-publish","format-standard","hentry","category-pharma-news"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7wLmz-84","jetpack_likes_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/3sixtypharma.com\/wp-json\/wp\/v2\/posts\/500"}],"collection":[{"href":"https:\/\/3sixtypharma.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/3sixtypharma.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/3sixtypharma.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/3sixtypharma.com\/wp-json\/wp\/v2\/comments?post=500"}],"version-history":[{"count":0,"href":"https:\/\/3sixtypharma.com\/wp-json\/wp\/v2\/posts\/500\/revisions"}],"wp:attachment":[{"href":"https:\/\/3sixtypharma.com\/wp-json\/wp\/v2\/media?parent=500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/3sixtypharma.com\/wp-json\/wp\/v2\/categories?post=500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/3sixtypharma.com\/wp-json\/wp\/v2\/tags?post=500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}